Dianthus Therapeutics (NASDAQ:DNTH) Hits New 12-Month High – Here’s What Happened

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high on Tuesday . The company traded as high as $107.99 and last traded at $101.00, with a volume of 837649 shares changing hands. The stock had previously closed at $105.60.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Wedbush increased their target price on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Price Performance

The business’s 50 day moving average is $89.24 and its two-hundred day moving average is $74.40. The firm has a market capitalization of $5.52 billion, a PE ratio of -24.46 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The business had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Insider Activity

In other news, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the transaction, the senior vice president owned 30,000 shares of the company’s stock, valued at $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 87,779 shares of company stock worth $7,985,235. 3.02% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after buying an additional 406,254 shares during the last quarter. UBS Group AG increased its stake in shares of Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after buying an additional 469,547 shares during the period. SG Americas Securities LLC purchased a new position in shares of Dianthus Therapeutics in the fourth quarter worth $765,000. BNP Paribas Financial Markets raised its holdings in Dianthus Therapeutics by 1,275.3% during the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after buying an additional 441,156 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Dianthus Therapeutics by 626.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,124 shares of the company’s stock valued at $2,681,000 after buying an additional 58,746 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.